PhD: Development of New Vaccine Manufacturing Platforms

Biological based medicines (e.g. vaccines, recombinant protein based drugs) have provided us with the ability to prevent, treat and cure a multitude of both communicable (infectious diseases) and non-communicable (non-infectious) diseases globally. This project will work with our GCRF partners in Thailand to develop new cell based (bacteria and mammalian cells) vaccine manufacturing platforms for the low cost, rapid development of animal and human vaccines. The objectives will be to use cell engineering and CRISPR/Cas9 genome scanning and editing approaches to identify targets that impact on vaccine production using model Vero, HEK, and as an alternative, Chinese hamster ovary (CHO), cell expression systems and then manipulate the target genes that show positive impact on viral vaccine production to generate stably engineered novel hosts for expression of viral and bacterial vaccines.

For further information please contact Prof Mark Smales Applications will be considered until the deadline of 18th May, 2018. Interviews will be held at the Kent site in the week of 21st May, 2018.

More details:
To apply please go to